Search

Displaying results 271 - 280 of 288 in total
  1. Drug

    Reslizumab

    go.drugbank.com/drugs/DB06602
    ApprovedInvestigational

    Reslizumab is marketed as Cinqaero in Europe. … randomized, placebo‑controlled trials in patients with severe asthma on currently available therapies, patients receiving reslizumab had fewer asthma attacks, and a longer time to the first attack compared

  2. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    Mifamurtide is marketed in Europe as Mepact for intravenous infusion.

  3. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

  4. Drug

    Sirolimus

    go.drugbank.com/drugs/DB00877
    ApprovedInvestigational

    [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. … formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex

  5. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    [L18438] Remdesivir was also approved by the European Commission on July 3, 2020. … Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues.

  6. Drug

    Hepatitis B Vaccine (Recombinant)

    go.drugbank.com/drugs/DB11627
    ApprovedInvestigationalWithdrawn

    In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier … The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization.

    Categories: Complex Mixtures
  7. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.

  8. Drug

    Infliximab

    go.drugbank.com/drugs/DB00065
    ApprovedInvestigational

    Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by...

    Categories: Complex Mixtures
  9. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth f...

    Categories: Complex Mixtures
  10. Drug

    Valsartan

    go.drugbank.com/drugs/DB00177
    ApprovedInvestigational

    [A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States.

    Mixtures: VALSACOR COMP 160/25MG, VALSACOR COMP 160/25MG